Related Experiment Video

Updated: Jun 21, 2026

Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of Cancer
09:13

Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of Cancer

Published on: January 5, 2024

T-oligo induces apoptosis in advanced prostate cancer cells

Munirathinam Gnanasekar1, Sivasakthivel Thirugnanam, Guoxing Zheng

  • 1Department of Biomedical Sciences, University of Illinois, College of Medicine, 1601 Parkview Avenue, Rockford, IL 61107, USA. mgnanas@uic.edu

Oligonucleotides
|August 1, 2009
PubMed

Insights

DNA oligonucleotides homologous to the telomere 3' overhang (T-oligo) show promise for treating advanced prostate cancer. T-oligo effectively inhibited proliferation and induced apoptosis in androgen-independent prostate cancer cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer is a leading male malignancy.
  • Hormone-refractory prostate cancer resists standard androgen ablation therapy.
  • Novel therapeutic strategies inducing apoptosis are crucial for advanced stages.

Purpose of the Study:

  • To investigate the therapeutic potential of DNA oligonucleotides homologous to the telomere 3' overhang (T-oligo) in prostate cancer.
  • To evaluate the effect of T-oligo on androgen-independent prostate cancer cells.

Main Methods:

  • Treatment of androgen-independent DU-145 prostate cancer cells with T-oligo.
  • Assessment of cell proliferation inhibition.
  • Evaluation of apoptosis induction.

Main Results:

  • T-oligo significantly inhibited the proliferation of DU-145 cells.
  • T-oligo treatment successfully induced apoptosis in DU-145 cells.
  • Androgen-independent prostate cancer cells demonstrated sensitivity to T-oligo.

Conclusions:

  • T-oligo exhibits potential as a novel therapeutic agent for prostate cancer.
  • The findings support further research into T-oligo for treating androgen-independent prostate cancer.
  • T-oligo represents a promising strategy for inducing apoptosis in resistant cancer cells.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...